Molecular test allows for continuous, noninvasive monitoring and tumor profiling
CHICAGO— June 2, 2018 – NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based, personalized healthcare company, unveiled Liquid GPS ™ a powerful next-generation tool for blood-based tumor profiling and quantitative monitoring.
NantHealth chose the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting to showcase the potential of Liquid GPS ™ — a blood-based molecular test that provides oncologists with a powerful tool to continuously monitor and profile tumors, an approach that is less invasive than a traditional biopsy.
Liquid GPS ™ expands upon NantHealth’s molecular analysis portfolio of products — which includes the tissue-based GPS Cancer ™ solution. Liquid GPS offers sophisticated analysis tools — looking beyond cfDNA to cfRNA. This technology allows more comprehensive profiling and trending of biomarkers that can’t be assessed by cfDNA alone. As a result, Liquid GPS ™ offers a richer portrait of a patient’s condition and offers more therapeutic targets, such as chemotherapy and immunotherapy, than a typical liquid biopsy.
“We believe the development of Liquid GPS is important to our broader vision for fighting cancer from a biological, rather than an anatomical perspective,” said Dr. Patrick Soon-Shiong, CEO of NantHealth “This test is a non-invasive way to achieve molecular insights that could help shape treatment and provide the oncologist and patients real-time information on the status of the cancer. This work builds on what NantHealth has already done with GPS Cancer as we focus on successfully analyzing and treating cancer at the molecular level.”
More information about the significance and potential applications of Liquid GPS ™ please visit the NANT booth at #7147
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-base, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth’s focused portfolio exemplifies its unique systems-based approach to personalized healthcare and integrates novel analysis with large-scale, biometric and phenotypic data to track patient outcomes and deliver precision medicine. For more information please visit www.nanthealth.com.
NANT MEDIA CONTACT
Jen Hodson
562-397-3639
Henry Jackson
310-486-8908